Table 2. Univariate and multivariate Cox proportional hazards analysis for recurrence-free survival to adjust risk associated with prognostic clinical features (n=50).
| Variables | RFS | |||
|---|---|---|---|---|
| Univariate HR (95% CI) | P-value | Multivariate HR (95% CI) | P-value | |
| Age (yr) | 1.05 (1.02–1.09) | 0.004 | 1.09 (1.05–1.14) | <0.001 |
| Stage (I, II vs. III, IV) | 3.15 (1.49–6.68) | 0.003 | 0.75 (0.19–2.92) | 0.682 |
| Tumor suspected as leiomyoma before surgery (no vs. yes) | 0.39 (0.16–0.96) | 0.041 | 0.83 (0.28–2.46) | 0.733 |
| Residual disease (no vs. yes) | 5.06 (2.09–12.26) | <0.001 | 5.07 (1.88–13.65) | <0.001 |
| Size (≤10 cm vs. >10 cm) | 2.90 (1.33–6.29) | 0.007 | 1.25 (0.48–3.23) | 0.652 |
| Symptoms (no vs. yes) | 2.36 (0.82–6.82) | 0.112 | ||
| Grade (1, 2 vs. 3) | 2.97 (1.36–6.48) | 0.006 | 0.49 (0.13–1.89) | 0.298 |
| Nuclear atypia (mild, moderate vs. severe) | 2.32 (1.09–4.95) | 0.029 | 2.09 (0.77–5.70) | 0.150 |
| Mitotic count (≤10 vs. >10/10 HPF) | 3.19 (1.28–7.92) | 0.013 | 3.98 (1.42–11.13) | 0.009 |
| Adjuvant chemotherapy (no vs. yes) | 3.72 (1.69–8.20) | 0.001 | 0.74 (0.17–3.20) | 0.684 |
| Adjuvant radiotherapy (no vs. yes) | 0.36 (0.15–0.89) | 0.028 | 0.21 (0.08–0.58) | 0.003 |
RFS, recurrence-free survival; HR, hazard ratio; CI, confidential interval; HPF, high-power field.